Blood tests to track cancer return in Korean patients with upper urinary tract cancer
Follows Korean adults with upper urinary tract cancer using blood tests for tumor DNA.
Plain-language title generated from the registry record
Registry title: Korean Prospective Upper Tract Urothelial Carcinoma Cohort
Key facts
- Where
- Seoul, South KoreaSee the site
Where in South Korea
- Samsung Medical CenterSeoul, South KoreaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Samsung Medical Center
- Trial code
- NCT07452432
- Record updated
- 5 March 2026
- Original description
This is a single-center, prospective, non-interventional observational cohort study designed to establish a structured recurrence monitoring platform in Korean patients with high-grade non-metastatic upper tract urothelial carcinoma (UTUC).Read full original descriptionShow less
Prospective Establishment of a Recurrence Monitoring Cohort in Korean Patients With Upper Tract Urothelial Carcinoma
This is a single-center, prospective, non-interventional observational cohort study designed to establish a structured recurrence monitoring platform in Korean patients with high-grade non-metastatic upper tract urothelial carcinoma (UTUC).
Eligible adult patients scheduled to receive neoadjuvant chemotherapy followed by radical nephroureterectomy will undergo circulating tumor DNA (ctDNA) sampling prior to chemotherapy initiation and once between 1-6 months after surgery.
Clinical, imaging, pathological, and longitudinal follow-up data will be prospectively collected to enable long-term monitoring of recurrence and survival outcomes.
The primary objective is to establish a prospective cohort integrating clinical and molecular data to support future translational research and recurrence prediction modeling in UTUC.
Inclusion: Age ≥ 19 years; Histologically confirmed high-grade upper tract urothelial carcinoma (renal pelvis and/or ureter); Clinical stage cT2-T4, cN0-1, M0; Planned neoadjuvant chemotherapy followed by radical nephroureterectomy; ECOG performance status 0-1; Adequate hematologic, hepatic, and renal function; Ability to provide written informed consent.
Exclusion: Evidence of distant metastasis (M1); Contraindication to cisplatin-based chemotherapy; Uncontrolled infection or severe comorbid medical condition; Pregnancy or breastfeeding; Any condition that, in the investigator's judgment, makes participation inappropriate.